[Transvaginal administration of estriol in postmenopausal urogynecological disorders].
The Authors carried out an open, non-controlled clinical trial in order to evaluate the clinical efficacy of estriol administered by the vaginal route (0.0125% cream) in cystourethropathic diseases caused by estrogenic insufficiency. All the 45 patients recruited (mean age 51.6 years) had been in menopause from 6 to 24 months; all of them have been treated with 0.5 mg estriol daily for 2 weeks; furthermore the treatment has been continued with the same dose of the hormone for the following 4 weeks but using an alternating daily administration. Among the parameters taken into consideration for the evaluation of the patients, a urodynamic examination has been also included. The final results have been considered very satisfactory showing a very significant improvement concerning every urodynamic test. Similar results have been obtained considering the symptomatologic point of view. On the basis of these results, the Authors concluded that estriol vaginal cream formulation represents a valuable therapeutical possibility in the treatment of patients affected by urogynecological diseases caused by estrogenic insufficiency in post-menopausal conditions.
Di Stefano
L
L
Clinica Ostetrica e Ginecologica, Università degli Studi de L'Aquila.
Patacchiola
F
F
Moscarini
M
M
D004305:Dose-Response Relationship, Drug; D004964:Estriol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D052776:Female Urogenital Diseases / Q000188:drug therapy*; D005831:Genital Diseases, Female / Q000188:drug therapy*; D006801:Humans; D008593:Menopause; D008875:Middle Aged; D017698:Postmenopause; D014563:Urodynamics / Q000187:drug effects; D014622:Vaginal Creams, Foams, and Jellies
D014622:Vaginal Creams, Foams, and Jellies; D004964:Estriol
L'estriolo transvaginale nei disturbi uroginecologici post-menopausali.